

This Page Is Inserted by IFW Operations
and is not a part of the Official Record.

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/40, C07D 487/22		A1	(11) International Publication Number: WO 90/12573 (43) International Publication Date: 1 November 1990 (01.11.90)
(21) International Application Number: PCT/US90/01680			
(22) International Filing Date: 29 March 1990 (29.03.90)			
(30) Priority data: 341,591 21 April 1989 (21.04.89) US			
(71) Applicant: HEALTH RESEARCH, INC. [US/US]; 66 Elm Street, Buffalo, NY 14263 (US).			
(72) Inventor: DOUGHERTY, Thomas, J. ; 2306 W. Oakfield, Grand Island, NY 14072 (US).			
(74) Agents: MURASHIGE, Kate, H. et al.; Irell & Manella, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).			
		(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), + CH, CH (European patent), CM (OAPI patent), DE, + DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent).	
		Published With international search report.	

(54) Title: BACTERIOCHLOROPHYLL-A DERIVATIVES USEFUL IN PHOTODYNAMIC THERAPY



(1)



(2)

(57) Abstract

Compounds of formula (1) or formula (2), wherein M is a non-paramagnetic metal selected from Mg^{+2} , Sn^{+2} , and Zn^{+2} , or represents 2 H^{+} each H^{+} bonded to one of the N atoms connected by the solid lines; R^1 is a saturated or unsaturated hydrocarbyl residue of 8-25C; each R^2 is independently selected from the group consisting of vinyl, ethyl, acetyl and 1-hydroxyethyl, and X is $COOR^3$, wherein R^3 is alkyl (1-4C); are useful in photodynamic therapy and diagnosis. These compounds photosensitize target biological substrates to irradiation, and treating said substrates with these sensitizers followed by irradiation leads to the impairment or destruction of the biological substrate. When administered systemically, these compounds accumulate in the undesired target biological substrate. The compounds can also be utilized *in vitro*, for example to destroy infectious cells or viruses in blood intended for transfusion.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LK	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LUX	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

-1-

5

BACTERIOCHLOROPHYLL-A DERIVATIVES
USEFUL IN PHOTODYNAMIC THERAPY

10

Technical Field

The invention relates to the field of photodynamic therapy and related treatment of in vitro samples using light-absorbing resonant ring systems and 15 irradiation. More specifically, the invention is directed to methods of in vivo photodynamic therapy and diagnosis and in vitro sterilization using bacteriochlorophyll-a and its related compounds.

20 Background Art

Photodynamic therapy using porphyrins and related compounds has, by now, a fairly long history. Early work, in the 1940s, demonstrated that porphyrin could be caused to fluoresce in irradiated tumor tissue. 25 The porphyrins appeared to accumulate in these tissues, and were capable of absorbing light in situ, providing a means to detect the tumor by the location of the fluorescence. A widely used preparation in the early stages of photodynamic treatment both for detection and 30 for therapy was a crude derivative of hematoporphyrin, also called hematoporphyrin derivative, HpD, or Lipson derivative prepared as described by Lipson and coworkers in J Natl Cancer Inst (1961) 26:1-8. Considerable work has been done using this preparation, and Dougherty and 35 coworkers reported the use of this derivative in treatment

-2-

of malignancy (Cancer Res (1978) 38:2628-2635; J Natl Cancer Inst (1979) 62:231-237).

Dougherty and coworkers prepared a more effective form of the hematoporphyrin derivative which 5 comprises a portion of HpD having an aggregate weight >10 kd. This form of the drug useful in photodynamic therapy is the subject of U.S. Patent 4,649,151, is commercially available, and is in clinical trials.

The general principles of the use of light-10 absorbing compounds, especially those related to porphyrins, has been well established as a treatment for tumors when administered systemically. The differential ability of these preparations to destroy tumor, as opposed to normal tissue, is due to the homing effect of these 15 preparations to the objectionable cells. (See, for example, Dougherty, T.J., et al., "Cancer: Principles and Practice of Oncology" (1982), V.T. de Vita, Jr., et al., eds., pp. 1836-1844.) Efforts have been made to improve the homing ability by conjugating hematoporphyrin 20 derivative to antibodies. (See, for example, Mew, D., et al., J Immunol (1983) 130:1473-1477.) The mechanism of these drugs in killing cells seems to involve the formation of singlet oxygen upon irradiation (Weishaupt, K.R., et al., Cancer Research (1976) pp. 2326-2329).

25 The use of hematoporphyrin derivative or its active components in the treatment of skin diseases using topical administration has also been described in U.S. Patent 4,753,958. In addition, the drugs have been used to sterilize biological samples containing infectious 30 organisms such as bacteria and virus (Matthews, J.L., et al., Transfusion (1988) ____:81-83). Various other photosensitizing compounds have also been used for this purpose, as set forth, for example, in U.S. Patent 4,727,027.

35 In general, the methods to use radiation sensitizers of a variety of structures to selectively

-3-

impair the functioning of biological substrates both in vivo and in vitro are understood in the art. The compounds useful in these procedures must have a differential affinity for the target biological substrate to be impaired or destroyed and must be capable of absorbing light so that the irradiated drug becomes activated in a manner so as to have a deleterious effect on the adjacent compositions and materials.

Because it is always desirable to optimize the performance of therapeutics and diagnostics, variations on the porphyrin drugs traditionally used in treatment and diagnosis have been sought. A number of general classes of photosensitizers have been suggested including phthalocyanines, psoralen-related compounds, and multicyclic compounds with resonant systems in general. Most similar to the compounds disclosed herein are various pheophorbide derivatives whose use in photodynamic therapy has been described in EPO Application 220686 to Nihon Metaphysics Company; ethylene diamine derivatives of pheophorbide for this purpose described in Japanese Application J85/000981 to Tama Seikayaku, K.K., and Japanese Application J88/004805 which is directed to 10-hydroxy pheophorbide-a. In addition, pheophorbide derivatized to a long chain hydrocarbyl group has been disclosed as useful in photodynamic therapy in U.S. Serial No. 221,804, filed 20 July 1988, assigned to the same assignee and incorporated herein by reference. In addition, Beems, E.M., et al., in Photochemistry and Photobiology (1987) 46:639-643 discloses the use as photosensitizers of two derivatives of bacteriochlorophyll-a -- bacteriochlorophyllin-a (also known as bacteriopheophorbide-a, which lacks the phytyl alcohol derivatized in bacteriochlorophyll-a) and bacteriochlorin-a (which lacks both the phytyl group and the Mg ion). These authors direct their attention to these derivatives as being


-4-


advantageous on the grounds of enhanced water solubility as compared to bactriochlorophyll-a.

The problem remains to find suitable photosensitizers useful in photodynamic therapy and diagnosis which are optimal for particular targets and particular contexts. It is unlikely whether a single compound or small group of compounds, while generally applicable, would be of maximum benefit in every instance. Thus, the invention provides an additional group of photosensitizing compounds which becomes part of the repertoire of candidates for use in specific therapeutic and diagnostic situations.

Disclosure of the Invention

The invention provides alternative methods of photodynamic therapy and diagnosis using a group of compounds related to the tetrahydroporphyrins, such as bacteriochlorophyll-a or -b or the corresponding bacteriochlorins. These compounds are of formula (1) or formula (2):





wherein M is a non-paramagnetic metal selected
 20 from Mg^{+2} , Sn^{+2} , and Zn^{+2} , or represents 2 H^+ , each H^+
 bonded to one of the N atoms connected by the solid lines;
 R^1 is a saturated or unsaturated hydrocarbyl
 residue of 8-25C;
 each R^2 is independently selected from the group
 25 consisting of vinyl, ethyl, acetyl and 1-hydroxyethyl, and
 X is $COOR^3$, wherein R^3 is alkyl (1-4C).
 Thus, in one aspect, the invention is directed
 to a method to effect the impairment or destruction of a
 target biological substrate which method comprises treat-
 30 ing the target substrate with an amount of the compound of
 formula 1 effective to photosensitize said substrate fol-
 lowed by irradiating said target substrate with radiation
 in a wavelength band absorbed by the compound of formula 1
 for a time effective to impair or destroy the substrate.
 35 In other aspects, the invention is directed to
 pharmaceutical compositions useful in the foregoing

-6-

method, and to diagnostic kits which include the compound of formula 1.

Brief Description of the Drawings

5 Figure 1 is a table showing the results of treatment with bacteriochlorophyll-a at a fixed total radiation energy.

10 Figure 2 shows the action spectrum constructed from the table of Figure 1.

15 Figure 3 shows the tumor response as compared to foot sensitization to bacteriochlorophyll-a as a function of time.

Modes of Carrying Out the Invention


15 Bacteriochlorophyll-a (bchl-a) is a tetrahydroporphyrin found in certain photosynthetic bacteria, for example, Rhodopseudomonas virdis. Bchl-a has the formula:

20

25

30

35



-7-

Bchl_a is essentially identical to the chlorophyll-a of higher plants except that ring B is in the dihydro form and the vinyl group in ring A is converted to an acetyl group. The wavelength absorption maximum of bchl_a is about 780 nm and the extinction coefficient in this region is quite high ($E_{780} = 75,000$). This long wavelength absorption is advantageous because light penetrates tissues 2-3 times more effectively at a wavelength nearly 800 nm versus lower wavelengths, e.g., 10 630 nm.

Bchl_a is readily obtained by extraction from bacterial sources, and is available commercially from Porphyrin Products, Logan, UT. Although the material is readily oxidized, especially in the presence of light, and 15 the magnesium ion is readily removed in the presence of dilute acid, bchl_a is sufficiently stable in vivo to be an effective phototherapeutic agent.

In bacteriochlorophyll-b, which can also readily be obtained from bacterial sources, R² in the B ring is 20 vinyl rather than ethyl. The other embodiments of R² can easily be prepared starting with bacteriochlorophyll-b by standard hydration of the vinyl group to obtain the 1-hydroxyethyl substituent, and mild oxidation to obtain the corresponding acetyl substituent. Similarly, the R² 25 substituent in ring A can be reduced to the 1-hydroxyethyl and/or dehydrated to vinyl and/or reduced to ethyl.

Conversion of the compounds of formula 1 to the compounds of formula 2 can readily be effected by opening of the cyclopentanone ring using known reagents, such as 30 alkaline solution in the presence of oxygen as described in "Porphyrins and Metalloporphyrins", Smith, K., ed. (1975) Elsevier Press, pp. 52-53. Although the phytyl group is removed in this reaction, reesterification to the desired R¹ can be effected by standard methods.

35 In general, alternate embodiments of R¹ or R³ in either formula 1 or formula 2 can be obtained by

-8-

transesterification or by hydrolysis and reesterification. In some instances, this esterification should be conducted on the compounds when they are in the form of the corresponding porphyrin or dihydroporphyrins obtained by oxidation, for example, using osmium tetroxide and then re-reducing to the tetrahydro form. In all of the conversions set forth above, it may be necessary to conduct the reactions in a certain order, to restore or remove the metal substituent and/or to utilize protective reactions and groups as is understood by practitioners in the art.

The compounds of formulas 1 and 2 are used for photodynamic therapy and diagnosis with respect to target biological substrates. By "target biological substrate" is meant any cells, viruses or tissues which are undesirable in the environment to which therapy or other corrective action, such as sterilization, is employed, or the location of which is desired to be known in an environment to which diagnosis is applied. For example, in a manner analogous to the use of the active fraction of hematoporphyrin derivative (HpD), as described in U.S. Patent 4,649,151, incorporated herein by reference; neoplastic tissue is effectively treated in vivo by virtue of the ability of the drug to accumulate preferentially in such tissue, and by virtue of the photosensitizing nature of the drug. In this instance, the target biological substrate is the neoplastic tissue. As described in this patent, the drug is injected into the subject, and permitted to clear normal tissue. Then the neoplastic tissue is exposed to radiation at a wavelength appropriate to its absorption spectrum. The patent further describes the synergistic effect of heat supplied, if desired, by infrared irradiation. In addition, the location of the tumor can be ascertained by the fluorescence of the drug.

In another application, Matthews, J.L., et al., 35 Transfusion (1988) :81-83, describe the use of the photosensitizing compounds HpD and the active fraction

-9-

thereof, designated DHE, in eradicating pathogens from fluids in vitro. This article describes techniques for treating blood or other biological fluids to eliminate pathogens such as protozoa, virus, bacteria, fungi, and so forth. Similarly, U.S. Patent 4,727,027 describes the use of furocoumarin in conjunction with irradiation by UV light for decontamination of blood products. In these instances, the target substrates are pathogens which may include a variety of "organisms" such as viruses and protozoa, as well as bacteria and fungi.

In U.S. Patent 4,753,958, topical treatment of skin diseases using photosensitizing drugs is described. In this instance, the target biological substrate is the infectious virus or cell carrying the disease. This too, may be a virus, bacterium, or other microorganism, including fungal infections.

For use in the method of the invention, the compounds of formula 1 and 2 are formulated using conventional excipients appropriate for the intended use. For systemic administration, in general, buffered aqueous compositions are employed, with sufficient nontoxic detergent to solubilize the active compound. As the compounds of formulas 1 and 2 are generally not very soluble in water, a solubilizing amount of such detergent is employed. Suitable nontoxic detergents include Tween-80, various bile salts, such as sodium glycholate, various bile salt analogs such as the fusidates. Alternate compositions utilize liposome carriers. The solution is buffered at neutral pH using conventional buffers such as Hank's solution, Ringer's solution, or phosphate buffer. Other components which do not interfere with the activity of the drug may also be included, such as stabilizing amounts of proteins, for example, serum albumin.

Systemic formulations can be administered by injection, such as intravenous, intraperitoneal, intramuscular, or subcutaneous injection, or can be

-10-

administered by transmembrane or transdermal techniques. Formulations appropriate for transdermal or transmembrane administration include sprays and suppositories containing penetrants, which can often be the detergents described 5 above.

For topical local administration, the formulation may also contain a penetrant and is in the form of an ointment, salve, liniment, cream, or oil. Suitable formulations for both systemic and localized topical 10 administration are found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA.

For use ex vivo to treat, for example, blood or plasma for transfusion or preparations of blood products such as Factor VIII, no special formulation is necessary, 15 but the compounds of formula 1 and 2 are dissolved in a suitable compatible solvent and mixed into the biological fluid at a suitable concentration, typically of the order of 1-100 ug/ml prior to irradiation.

For photodynamic therapeutic and diagnostic applications, suitable dosage ranges will vary with the mode 20 of application and the choice of the compound, as well as the nature of the condition being treated or diagnosed. However, in general, suitable dosages are of the order of 0.1-50 mg/kg body weight, preferably 1-3 mg/kg. For 25 topical administration, typically amounts on the order of 50-100 mg total are employed.

The general procedures for photodynamic therapy and diagnosis in vivo are analogous to those described in U.S. Patent 4,649,141; those for ex vivo treatment are 30 analogous to those described by Matthews, J.L., et al., Transfusion (supra); topical methods are analogous to those described in U.S. Patent 4,753,958; all are incorporated herein by reference.

Briefly, for systemic administration, a suitable 35 time period after administration, typically from several hours to two days is allowed to elapse in order to permit

-11-

concentration of the drug of formula 1 or 2 in the target biological substrate. In general, this substrate will be a tumor, and the localization of the compound of formula 1 or 2 can be monitored by measuring the fluorescence or 5 absorption of the target tissue as compared to background. After localization has been accomplished, the target biological substrate is irradiated with a suitable band of irradiation, in the case of the compounds of formula 1, in the range of 750-800 nm at a rate of 5 mW/cm^2 - 0.75 W/cm^2 , 10 and a total energy of $100-1000 \text{ J/cm}^2$.

For topical treatment, localization is immediate, and the corresponding radiation can be provided immediately. For treatment of biological fluids ex vivo, again, no localization interval is required, and radiation 15 is applied on the order of $1-10 \text{ J/cm}^2$. Because penetration of tissue is not required, lower total energy can be employed.

The following example, directed to bchl-a, is intended to illustrate but not to limit the invention. 20 The remaining compounds of formulas 1 and 2 have similar absorption spectra as they contain the same tetrahydroporphyrin resonance system, and have similar solubilities.

25

Example 1

Formulation of bchl-a

Bacteriochlorophyll-a, obtained at >90% purity from Porphyrin Products (Logan, UT) was dissolved at a concentration of 5 mg/ml in Tween-80 (Sigma) by stirring 30 for several hours or overnight. The resulting solution was mixed with 9 volumes of Hank's buffer solution with agitation until all of the detergent solution was dissolved. Any remaining particulate matter is removed by filtration and the concentration of the final solution is 35 determined spectrophotometrically using a 1:100 dilution in distilled water ($OD_{780} = 87.3$ for 1 mg/ml of

-12-

concentrate). In general, if the initial solution of bchla is conducted carefully, the resulting formulation has a concentration of bchla of 0.5 mg/ml.

5

Example 2

Effect of bchla on Tumors

DBA2/HaD mice were transplanted with SMT-F tumors. When the subcutaneous tumors reached 4.5-5.5 mm in diameter, the mice, in groups of five, were injected 10 intravenously with the bchla solution of Example 1 in doses of 5-30 mg/kg. At a time 1 hour-5 days later, the tumor, previously shaved and depilated, plus a margin of 2-3 mm was exposed to radiation of a wavelength in the range 630-800 nm using a Spectraphysics argon dye laser 15 with Exciton LDS751 dye, tunable over the 700-800 nm range or a diode laser--e.g., Spectra Diode emitting in the 750-850 nm range or a Xenon arc lamp filtered with an interference filter to pass 90% of the 700 nm light \pm 60 nm at dose rates of 75-150 mW/cm². When the Xenon system was 20 used, mild hyperthermia resulted (42°C at 160 mW/cm²). It is not known whether this temperature rise acts synergistically with bchla as has been shown with HpD and its active fraction.

Tumor response is shown in the table of Figure 1 25 for the seventh day after light treatment which indicates regression, and at a time point at least 30 days after light treatment, which would indicate cure, if there had been no regrowth.

As shown in Figure 1 good response to bchla was 30 obtained, for example, after 2 hours at 5 mg/kg in the 670-790 nm range and after 24 hours after injection with 10 mg/kg and irradiated at 680-780 nm.

Figure 2 shows the action spectrum along with the absorption spectra of bchla, pheophytin (demetalated 35 bchla, found in vivo) and for chlorophyll (oxidized bchla, theoretically found in vivo). The "X's represent the 7

-13-

day response when 270 J/cm² were used 2 hours after the administration of 5 mg/kg; the squares represent the 7 day response when 270 J/cm² were administered 24 hours after administration of 10 mg/kg, and the circles represent the 30 day (cure) response, all as a function of wavelength of light used to treat the tumor.

Example 3

Determination of Therapeutic Ratio

10 One of the undesirable side effects of photodynamic therapy using certain compounds is cutaneous photosensitivity unrelated to the target biological substrate. Accordingly, the effect of the treatment on the photosensitivity of the foot of the treated mice was measured. The response of the foot was measured as erythema and/or edema (or loss of skin or further damage).

15 The results are shown in Figure 3. The left ordinate shows the percentage of tumors which responded; the right ordinate is an arbitrary scale for the foot response wherein 1.0 represents severe erythema and edema; 0.1 represents little effect, and 0.5 represents a moderate reaction. The results show that for bchla, the sensitivity of the tumor and the skin of the foot declined concomitantly, while for the active component of 20 hematoporphyrin derivative designated DHE, the sensitivity persists for more than 10 days after injection. Thus, with DHE the tissue (foot) would be sensitive to light (for example, sunlight) for an extended period of time (30 days in humans), whereas for bchla, sensitivity could be 25 expected to persist for only a few days.

Example 4

Metabolism of bchla

30 Uptake and clearance of bchla in tumor and liver were measured by extraction of the tumor or liver tissue with 1:1MeOH:CH₂Cl₂, followed by HPLC analysis. The

-14-

levels of bchla in tumor and liver after injection of bchla are shown in Table 1.

Table 1
bchla Uptake in DBA/2 Ha Mice in SMT-F Tumor

	<u>Dose bchla (mg/kg)</u>	<u>Time After Injection</u>	<u>Tissue Level</u> <u>Tumor</u>	<u>(ug/g)</u> <u>Liver</u>
10	10	2 h	6.14	44
	10	24 h	-	49.4*
	20	2 h	16	-
	20	24 h	10-19.7*	-
	10	48 h	10.7*	-

15 *Values at time intervals of 1 day or more are uncertain since preliminary experiments indicate conversion to other components (see below).

These results show that both tumor and liver have high levels of the compound after 2 hours and that these levels are maintained for as long as 24 or 48 hours.

However, partial conversion to bacterio-pheophytin occurs at 24 hours or more in tumor and 2 hours in liver. Two hours after injection, the tumor contains essentially only bchla with a small amount of material wherein the phytyl group has hydrolyzed; at 48 hours the tumor contains mainly material without phytyl and without Mg. At 24 hours the material in tumor is demetallized but still contains phytyl.

30

Example 5

35 Comparison was made using bchla at 20 mg/kg with
irradiation after 1 hour at 270 J/cm² at 780 nm, and DHE
at 5 mg/kg after 1 hour at 270 J/cm² at 630 nm. Animals
with tumors approximately 1 cm in depth were used in the

-15-

comparison. Histological sections were obtained the day following treatment, fixed and stained. A comparison using a total of 4 animals showed a necrotic depth of 5-6 mm for DHE and approximately 9 mm for bchl_a, consistent with deeper penetration of 780 nm light compared to 630 nm light.

10

15

20

25

30



35

-16-

Claims

1. The use of a compound of formula (1) or
formula (2):

5



wherein M is a nonparamagnetic metal selected from Mg^{+2} , Sn^{+2} , and Zn^{+2} , or r presents 2 H^+ , each H^+ bonded to one of the N atoms connected by the solid lines;

R^1 is a saturated or unsaturated hydrocarbyl

5 residue of 8-25C;

each R^2 is independently selected from the group consisting of vinyl, ethyl, acetyl and 1-hydroxyethyl, and X is $COOR^3$, wherein R^3 is alkyl (1-4C); for the

10 manufacture of a composition useful in a method to effect
the destruction or impairment of undesired target biological
substrates, which method comprises


treating said biological substrates with said composition and

irradiating the treated biological substrates

15 with radiation having a wavelength absorbed by the compound of formula (1) or (2).

2. A composition for use in a method to effect
the destruction or impairment of undesired target biological
substrates, which composition comprises

a compound of formula (1) or formula (2):



-18-


5

10

15

20

(2)



wherein M is a nonparamagnetic metal selected from Mg^{+2} , Sn^{+2} , and Zn^{+2} , or represents 2 H^+ bonded to 25 one of the N atoms connected by the solid lines;

R^1 is a saturated or unsaturated hydrocarbyl residue of 8-25C;

each R^2 is independently selected from the group consisting of vinyl, ethyl, acetyl and 1-hydroxyethyl, and 30

X is $COOR^3$, wherein R^3 is alkyl (1-4C) as active ingredient in admixture with at least one pharmaceutically acceptable excipient, wherein said method comprises treating said biological substrates with said composition and irradiating the treated biological substrates with 35 radiation having a wavelength absorbed by the compound of formula (1) or (2).

-19-

3. The composition of claim 2 wherein R^1 is a phytyl residue and M is Mg^{+2} .


4. The composition of claim 3 wherein one R^2 is 5 acetyl and the other R^2 is vinyl or ethyl.

5. The composition of claim 4 wherein the compound of formula (1) is bacteriochlorophyll-a or bacterio-chlorophyll-b.


10

6. A method to effect the destruction or impairment of undesired target biological substrates in a biological fluid which method comprises:

15 a) treating said biological substrates with a compound of formula (1) or formula (2):



-20-



wherein M is a nonparamagnetic metal selected from Mg^{+2} , Sn^{+2} , and Zn^{+2} , or represents 2 H^+ , each H^+ bonded to one of the N atoms connected by the solid lines;

20 R¹ is a saturated or unsaturated hydrocarbyl residue of 8-25C;

25 each R² is independently selected from the group consisting of vinyl, ethyl, acetyl and 1-hydroxyethyl, and X is COOR³, wherein R³ is alkyl (1-4C);

30 said compound of formula (1) or (2) being in an amount effective to photosensitize said biological substrates to the resultant of irradiation absorbed by the compound of formula (1) or (2); and

(b) irradiating the treated biological substrates with radiation having a wavelength absorbed by the compound of formula (1) or (2).

7. The method of claim 6 wherein the biological fluid is blood or blood plasma.

-21-

8. The method of claim 6 wherein the target biological substrate is selected from the group consisting of tumor cells, bacterial cells, fungi, protozoa and viruses.

5 9. The method of claim 6 wherein the compound of formula (1) is bacteriochlorophyll-a or bacterio-chlorophyll-b.

10. The method of claim 6 wherein the radiation is generated by a diode laser.

15

20

25

30

35

Tumor Response in the SMT-F Tumor (DBA/2 Na Mice)

<u>Drug Dose</u> <u>g/kg, i.v.)</u>	<u>Time Interval</u> <u>(h)</u>	<u>Wavelength</u> <u>(nm)</u>	<u>Light Dose</u> <u>(J/cm²)</u>	<u>Tumor Response</u> <u>Day 7</u>	<u>Day 30+</u>
3.0	2	680	270	3/5	0
"	2	750	270	3/6	0
"	2	780	270	3/6	0
5.0	2	780	270	18/26 (69%)	4/26 (15%)
"	2	630	270	2/6	0
"	2	670	270	6/6	0
"	2	726	270	5/5	0
"	2	740	270	3/3	0
"	2	760	270	4/4	3/4
"	2	790	270	3/6	1/6
"	2	800	270	2/5	0
10.0	24	630	270	0/5	0
"	24	680	270	5/5	0
"	24	750	270	9/10	0
"	24	780	270	9/12	0
"	24	799	270	0	0
5.0	1	780	540	3/5	0
10	1	780	540	5/5	4/5
10	2	780	540	4/4	0
20	2	780	540	5/5	1/5
10	24	780	540	4/30	0
20	24	780	540	4/9	0
30	24	780	540	4/5	0
10	2	780	1080	2/5	1/5
10	24	780	1080	10/13	0
20	24	780	1080	4/5	1/5
20	48	780	1080	5/5	0
20	72	780	1080	0/7	0
20	96	780	1080	2/5	0
20	120	780	1080	0/5	0
20	1	780	1080	3/3	1/3
20	2	780	1080	4/4	2/4

Note:

1. Data from groups containing fewer than 10 mice are not statistically significant and should be considered preliminary.
2. Curability (i.e. >30 day response) in this tumor system likely depends upon damage to normal vasculature adjacent to the tumor and may not be relevant to humans.

2 / 3


Action Spectrum - b chla (SMT-F), 270 Joules/cm²

FIG. 2

3 / 3




FIG. 3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US90/01680

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC5 A61K 31/40; C07D 487/22

U.S. Cl. 514/185,410; 540/145

II. FIELDS SEARCHED

Classification System	Minimum Documentation Searched ⁷	Classification Symbols
	514/185,410; 540/145	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Photochemistry and Photobiology, vol. 46, No. 5, 1987, Eva M. Beems et al, "Photosensitizing Properties of Bacteriochlorophyllin a and Bacteriochlorin a Two Derivatives of Bacteriochlorophyll a," pages 639 to 643, see pages 639	1-10
A	US, 4,649,151 (DOUGHERTY ET AL) 10 March 1987 see the abstract	1-10

* Special categories of cited documents: ¹⁰

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

23 April 1990

Date of Mailing of this International Search Report

25 MAY 1990

International Searching Authority

ISA/US

Signature of Authorized Officer

Richard L. Raymond *Nguyet Ho Nguyen*
Ho NGUYEN